Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

Cancer Invest. 2018 Feb 7;36(2):165-174. doi: 10.1080/07357907.2018.1430818. Epub 2018 Feb 2.


Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort. Based on the optimized model for overall survival, comprising performance status and p53 expression, a prognostic index is established.

Keywords: Bevacizumab; Cancer biomarkers; Glioma; Prognosis and response predictions; Recurrent.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab / administration & dosage
  • Biomarkers, Tumor / analysis*
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Glioma / drug therapy*
  • Humans
  • Irinotecan
  • Neoplasm Grading
  • Neoplasm Recurrence, Local / diagnosis*
  • Neoplasm Recurrence, Local / epidemiology
  • Neoplasm Recurrence, Local / metabolism
  • Prevalence
  • Survival Rate


  • Biomarkers, Tumor
  • Bevacizumab
  • Irinotecan
  • Camptothecin